Image source: Getty Images
CSL vs Telstra shares: Which ASX blue chip has a better outlook?
Whether you're chasing consistent dividends, sector-leading growth, or just plain blue-chip reliability, you've probably considered CSL Ltd (ASX: CSL) and Telstra Group Ltd (ASX: TLS). As two of the ASX's heavyweights—one a global biotech leader, the other Australia's telecoms giant—they represent very different ways to build wealth. Let's break down their latest numbers and outlook to see which one I think offers the better opportunity right now.
The case for CSL
CSL sits among the world's top biotech companies, developing blood plasma therapies, vaccines, and specialty medicines to tackle rare and serious diseases. The company has a 100-year history and global reach, with major businesses in CSL Behring (biotherapies), CSL Seqirus (vaccines), and CSL Vifor (nephrology). Its scale includes one of the largest plasma collection networks worldwide and a presence in over 40 countries—a mark of how central it is to the sector.
Looking at what stands out right now:
- Market cap: At $94.39 billion, CSL is bigger than most ASX peers, showing its dominant position in healthcare.
- P/E ratio: 18.12, which looks more reasonable compared to its own history and relative to many large healthcare rivals globally.
- Dividend yield: 2.06% may look modest, but CSL tends to focus on reinvesting for future growth, and its size supports a robust pipeline.
However, I did notice CSL's latest reported earnings per share figure is negative (-5.350). This doesn't line up with the positive P/E ratio reported, so it likely reflects an adjusted or forward-looking figure. Still, the main story here is solid blue-chip stability with upside potential tied to new therapies and global healthcare demand.
The case for Telstra
If you want reliable income with a home-grown focus, Telstra ticks a lot of boxes. As Australia's largest telecommunications provider, it's been the go-to for phone and internet services for decades and has now diversified into four subsidiaries covering consumer, infrastructure, towers, and international services.
Key numbers that jump out for Telstra:
- Dividend yield: 4.24%—a key reason Telstra is a dividend investor staple, especially with fully franked payments (franking averaging over 90%).
- Market cap: $54.91 billion—a big business, but still a fair way behind CSL's size and global profile.
- P/E ratio: 24.87, suggesting the market expects growth or at least steadiness from its earnings base.
And with an earnings per share of $0.199 and consistent dividend growth in recent years, Telstra appeals to those who want regular, tax-effective pay-outs. Its position as a telco utility also brings defensive appeal, even though the sector isn't known for rapid growth.
Valuation comparison
Here's how the most relevant valuation and income metrics stack up, side by side:
| CSL | Telstra | |
|---|---|---|
| Market Cap | $94.39 billion | $54.91 billion |
| P/E Ratio | 18.12 | 24.87 |
| Dividend Yield | 2.06% | 4.24% (franked) |
| Earnings per Share | -5.350 | 0.199 |
Note: CSL's P/E ratio appears inconsistent with its reported negative EPS, likely due to the P/E using an adjusted or forward measure. Telstra sports a much higher dividend yield with heavy franking, while CSL's is lower and unfranked. Telstra is trading at a higher P/E, so investors are paying more for each dollar of current earnings.
Recent share price momentum
Comparing recent share price performance up to 23 October 2026:
- CSL: Closed at $196.70 on 23 Oct 2026, up 16.3% year to date—a solid recovery and outperformance versus the broader market.
- Telstra Group: Closed at $4.95 on 23 Oct 2026, up 5.95% for the year—steady but less impressive growth.
Which is the better buy?
If you want reliable, fully franked income, Telstra is hard to beat with its twice-the-market dividend yield and steady utility-like cash flows. But if you're after growth and sector leadership, CSL Limited is my pick. The share price momentum for CSL has easily outpaced Telstra so far this year, and its lower P/E—despite some earnings noise in the figures—suggests there's still appetite for its global pipeline. For my money, I'd lean towards CSL as the better blue-chip buy today for long-term growth, especially for those who don't need maximum dividends right now. Telstra is great for income and stability, but CSL, to me, has the superior outlook if you want to build wealth over time.
